The emerging role of mass spectrometry-based proteomics in drug discovery.
Journal
Nature reviews. Drug discovery
ISSN: 1474-1784
Titre abrégé: Nat Rev Drug Discov
Pays: England
ID NLM: 101124171
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
accepted:
19
01
2022
pubmed:
31
3
2022
medline:
9
9
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
Proteins are the main targets of most drugs; however, system-wide methods to monitor protein activity and function are still underused in drug discovery. Novel biochemical approaches, in combination with recent developments in mass spectrometry-based proteomics instrumentation and data analysis pipelines, have now enabled the dissection of disease phenotypes and their modulation by bioactive molecules at unprecedented resolution and dimensionality. In this Review, we describe proteomics and chemoproteomics approaches for target identification and validation, as well as for identification of safety hazards. We discuss innovative strategies in early-stage drug discovery in which proteomics approaches generate unique insights, such as targeted protein degradation and the use of reactive fragments, and provide guidance for experimental strategies crucial for success.
Identifiants
pubmed: 35351998
doi: 10.1038/s41573-022-00409-3
pii: 10.1038/s41573-022-00409-3
doi:
Substances chimiques
Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
637-654Informations de copyright
© 2022. Springer Nature Limited.
Références
Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239–1249 (2011).
pubmed: 21091654
pmcid: 3058157
doi: 10.1111/j.1476-5381.2010.01127.x
Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507–519 (2011). This Review provides an excellent analysis of discovery strategies and molecular mode of action of approved drugs.
pubmed: 21701501
doi: 10.1038/nrd3480
Clark, M. A. et al. Design, synthesis and selection of DNA-encoded small-molecule libraries. Nat. Chem. Biol. 5, 647–654 (2009).
pubmed: 19648931
doi: 10.1038/nchembio.211
Renaud, J. P. et al. Biophysics in drug discovery: impact, challenges and opportunities. Nat. Rev. Drug Discov. 15, 679–698 (2016).
pubmed: 27516170
doi: 10.1038/nrd.2016.123
Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80–84 (2014).
pubmed: 24336569
doi: 10.1126/science.1246981
Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).
pubmed: 25430774
doi: 10.1126/science.1258096
Waring, M. J. et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475–486 (2015). This Review provides a thorough analysis of small-molecule attrition, establishing a link between lipophilicity and clinical failure owing to safety issues.
pubmed: 26091267
doi: 10.1038/nrd4609
Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 12, 569 (2013).
pubmed: 23903212
doi: 10.1038/nrd4090
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A. & Corn, J. E. Cornerstones of CRISPR–Cas in drug discovery and therapy. Nat. Rev. Drug Discov. 16, 89–100 (2017).
pubmed: 28008168
doi: 10.1038/nrd.2016.238
Paananen, J. & Fortino, V. An omics perspective on drug target discovery platforms. Brief. Bioinform 21, 1937–1953 (2019).
pmcid: 7711264
doi: 10.1093/bib/bbz122
Connelly, C. M., Moon, M. H. & Schneekloth, J. S. Jr. The emerging role of RNA as a therapeutic target for small molecules. Cell Chem. Biol. 23, 1077–1090 (2016).
pubmed: 27593111
pmcid: 5064864
doi: 10.1016/j.chembiol.2016.05.021
Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 537, 347–355 (2016).
pubmed: 27629641
doi: 10.1038/nature19949
Larance, M. & Lamond, A. I. Multidimensional proteomics for cell biology. Nat. Rev. Mol. Cell Biol. 16, 269–280 (2015).
pubmed: 25857810
doi: 10.1038/nrm3970
Smith, L. M. & Kelleher, N. L., Consortium for Top Down Proteomics. Proteoform: a single term describing protein complexity. Nat. Methods 10, 186–187 (2013).
pubmed: 23443629
pmcid: 4114032
doi: 10.1038/nmeth.2369
Aebersold, R. et al. How many human proteoforms are there? Nat. Chem. Biol. 14, 206–214 (2018).
pubmed: 29443976
pmcid: 5837046
doi: 10.1038/nchembio.2576
Ponomarenko, E. A. et al. The size of the human proteome: the width and depth. Int. J. Anal. Chem. 2016, 7436849 (2016).
pubmed: 27298622
pmcid: 4889822
doi: 10.1155/2016/7436849
Franco-Serrano, L. et al. MultitaskProtDB-II: an update of a database of multitasking/moonlighting proteins. Nucleic Acids Res. 46, D645–D648 (2018).
pubmed: 29136215
doi: 10.1093/nar/gkx1066
Budayeva, H. G. & Kirkpatrick, D. S. Monitoring protein communities and their responses to therapeutics. Nat. Rev. Drug Discov. 19, 414–426 (2020).
pubmed: 32139903
doi: 10.1038/s41573-020-0063-y
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16, 531–543 (2017).
pubmed: 28685762
doi: 10.1038/nrd.2017.111
Scudellari, M. Protein-slaying drugs could be the next blockbuster therapies. Nature 567, 298–300 (2019).
pubmed: 30894734
doi: 10.1038/d41586-019-00879-3
Bekker-Jensen, D. B. et al. An optimized shotgun strategy for the rapid generation of comprehensive human proteomes. Cell Syst. 4, 587–599.e584 (2017).
pubmed: 28601559
pmcid: 5493283
doi: 10.1016/j.cels.2017.05.009
Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010). This paper reports how chemoproteomics enabled the discovery that thalidomide binds to an E3 ligase complex.
pubmed: 20223979
doi: 10.1126/science.1177319
Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301–305 (2014).
pubmed: 24292625
doi: 10.1126/science.1244851
Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123 (2010).
pubmed: 21068722
pmcid: 5415086
doi: 10.1038/nature09589
Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011).
pubmed: 21964340
pmcid: 3679520
doi: 10.1038/nature10509
Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307–321 (2012).
pubmed: 22500798
pmcid: 3328787
doi: 10.1016/j.cell.2012.02.053
Koch, H., Busto, M. E., Kramer, K., Medard, G. & Kuster, B. Chemical proteomics uncovers EPHA2 as a mechanism of acquired resistance to small molecule EGFR kinase inhibition. J. Proteome Res. 14, 2617–2625 (2015).
pubmed: 25963923
doi: 10.1021/acs.jproteome.5b00161
Sos, M. L. et al. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 8, 1037–1048 (2014).
pubmed: 25127139
pmcid: 4294625
doi: 10.1016/j.celrep.2014.07.010
Schirle, M. & Jenkins, J. L. Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov. Today 21, 82–89 (2016).
pubmed: 26272035
doi: 10.1016/j.drudis.2015.08.001
Schenone, M., Dančík, V., Wagner, B. K. & Clemons, P. A. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232–240 (2013).
pubmed: 23508189
pmcid: 5543995
doi: 10.1038/nchembio.1199
Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014).
pubmed: 25278616
doi: 10.1126/science.1255784
Molina, D. M. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013). This paper is a landmark study introducing the CETSA.
doi: 10.1126/science.1233606
Lomenick, B. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl Acad. Sci. USA 106, 21984–21989 (2009).
pubmed: 19995983
pmcid: 2789755
doi: 10.1073/pnas.0910040106
Feng, Y. et al. Global analysis of protein structural changes in complex proteomes. Nat. Biotechnol. 32, 1036–1044 (2014).
pubmed: 25218519
doi: 10.1038/nbt.2999
Taunton, J., Hassig, C. A. & Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408–411 (1996).
pubmed: 8602529
doi: 10.1126/science.272.5260.408
Harding, M. W., Galat, A., Uehling, D. E. & Schreiber, S. L. A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase. Nature 341, 758–760 (1989). This article reports the discovery of immunophilins as receptors of macrolides.
pubmed: 2477715
doi: 10.1038/341758a0
Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin–receptor complex. Nature 369, 756–758 (1994).
pubmed: 8008069
doi: 10.1038/369756a0
Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208–31219 (2005).
pubmed: 15975926
doi: 10.1074/jbc.M500806200
Ong, S.-E. et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl Acad. Sci. USA 106, 4617–4622 (2009).
pubmed: 19255428
pmcid: 2649954
doi: 10.1073/pnas.0900191106
Wright, M. H. & Sieber, S. A. Chemical proteomics approaches for identifying the cellular targets of natural products. Nat. Prod. Rep. 33, 681–708 (2016).
pubmed: 27098809
pmcid: 5063044
doi: 10.1039/C6NP00001K
Oda, Y. et al. Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem. 75, 2159–2165 (2003).
pubmed: 12720356
doi: 10.1021/ac026196y
Schirle, M., Bantscheff, M. & Kuster, B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem. Biol. 19, 72 (2012).
pubmed: 22284356
doi: 10.1016/j.chembiol.2012.01.002
Ruoho, A. E., Kiefer, H., Roeder, P. E. & Singer, S. J. The mechanism of photoaffinity labeling. Proc. Natl Acad. Sci. USA 70, 2567–2571 (1973).
pubmed: 4517671
pmcid: 427057
doi: 10.1073/pnas.70.9.2567
Dubinsky, L., Krom, B. P. & Meijler, M. M. Diazirine based photoaffinity labeling. Bioorg. Med. Chem. 20, 554–570 (2012).
pubmed: 21778062
doi: 10.1016/j.bmc.2011.06.066
Jones, L. H. Cell permeable affinity- and activity-based probes. Future Med. Chem. 7, 2131–2141 (2015).
pubmed: 26511518
doi: 10.4155/fmc.15.100
Murale, D. P., Hong, S. C., Haque, M. M. & Lee, J.-S. Photo-affinity labeling (PAL) in chemical proteomics: a handy tool to investigate protein-protein interactions (PPIs). Proteome Sci. 15, 14 (2017).
pubmed: 28652856
pmcid: 5483283
doi: 10.1186/s12953-017-0123-3
Rutkowska, A. et al. A modular probe strategy for drug localization, target identification and target occupancy measurement on single cell level. ACS Chem. Biol. 11, 2541–2550 (2016).
pubmed: 27384741
doi: 10.1021/acschembio.6b00346
Sobotzki, N. et al. HATRIC-based identification of receptors for orphan ligands. Nat. Commun. 9, 1519 (2018).
pubmed: 29666374
pmcid: 5904110
doi: 10.1038/s41467-018-03936-z
Colca, J. R. et al. Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 286, E252–E260 (2004).
pubmed: 14570702
doi: 10.1152/ajpendo.00424.2003
Colca, J. R. et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT) — relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE 8, e61551 (2013).
pubmed: 23690925
pmcid: 3655167
doi: 10.1371/journal.pone.0061551
Divakaruni, A. S. et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl Acad. Sci. USA 110, 5422–5427 (2013).
pubmed: 23513224
pmcid: 3619368
doi: 10.1073/pnas.1303360110
Mellacheruvu, D. et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat. Methods 10, 730–736 (2013).
pubmed: 23921808
pmcid: 3773500
doi: 10.1038/nmeth.2557
Keilhauer, E. C., Hein, M. Y. & Mann, M. Accurate protein complex retrieval by affinity enrichment mass spectrometry (AE-MS) rather than affinity purification mass spectrometry (AP-MS). Mol. Cell Proteom. 14, 120–135 (2015).
doi: 10.1074/mcp.M114.041012
Choi, H., Glatter, T., Gstaiger, M. & Nesvizhskii, A. I. SAINT-MS1: protein-protein interaction scoring using label-free intensity data in affinity purification-mass spectrometry experiments. J. Proteome Res. 11, 2619–2624 (2012).
pubmed: 22352807
pmcid: 3744231
doi: 10.1021/pr201185r
Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620 (2009).
pubmed: 19759537
doi: 10.1038/nature08356
Krastel, P. et al. Nannocystin a: an elongation factor 1 inhibitor from myxobacteria with differential anti-cancer properties. Angew. Chem. Int. Ed. 54, 10149–10154 (2015).
doi: 10.1002/anie.201505069
Ko, C.-C. et al. Chemical proteomics identifies heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of quercetin in its anti-cancer effects in PC-3 cells. J. Biol. Chem. 289, 22078–22089 (2014).
pubmed: 24962584
pmcid: 4139222
doi: 10.1074/jbc.M114.553248
Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007). This is the first paper to introduce mixed kinase inhibitor beads (kinobeads) for chemoproteomic selectivity profiling of kinase inhibitors.
pubmed: 17721511
doi: 10.1038/nbt1328
Patricelli, M. P. et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18, 699–710 (2011).
pubmed: 21700206
pmcid: 3142620
doi: 10.1016/j.chembiol.2011.04.011
Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744 (2009).
pubmed: 19749761
doi: 10.1038/nmeth.1373
Eberl, H. C. et al. Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. Sci. Rep. 9, 14159 (2019).
pubmed: 31578349
pmcid: 6775116
doi: 10.1038/s41598-019-50335-5
Ballell, L. et al. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem 8, 313–321 (2013).
pubmed: 23307663
pmcid: 3743164
doi: 10.1002/cmdc.201200428
Abrahams, K. A. et al. Identification of KasA as the cellular target of an anti-tubercular scaffold. Nat. Commun. 7, 12581 (2016).
pubmed: 27581223
pmcid: 5025758
doi: 10.1038/ncomms12581
Wyllie, S. et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature 560, 192–197 (2018).
pubmed: 30046105
pmcid: 6402543
doi: 10.1038/s41586-018-0356-z
Cox, J. A. G. et al. THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. Nat. Microbiol. 1, 15006 (2016).
pubmed: 27571973
doi: 10.1038/nmicrobiol.2015.6
Niphakis, M. J. & Cravatt, B. F. Enzyme inhibitor discovery by activity-based protein profiling. Annu. Rev. Biochem. 83, 341–377 (2014).
pubmed: 24905785
doi: 10.1146/annurev-biochem-060713-035708
Hagenstein, M. C. et al. Affinity-based tagging of protein families with reversible inhibitors: a concept for functional proteomics. Angew. Chem. Int. Ed. 42, 5635–5638 (2003).
doi: 10.1002/anie.200352084
Bantscheff, M., Scholten, A. & Heck, A. J. R. Revealing promiscuous drug–target interactions by chemical proteomics. Drug Discov. Today 14, 1021–1029 (2009).
pubmed: 19596079
doi: 10.1016/j.drudis.2009.07.001
Zhao, Q. et al. Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes. J. Am. Chem. Soc. 139, 680–685 (2017).
pubmed: 28051857
pmcid: 5858558
doi: 10.1021/jacs.6b08536
Dalton, S. E. et al. Selectively targeting the kinome-conserved lysine of PI3Kδ as a general approach to covalent kinase inhibition. J. Am. Chem. Soc. 140, 932–939 (2018).
pubmed: 29232121
doi: 10.1021/jacs.7b08979
Klaeger, S. et al. Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors. ACS Chem. Biol. 11, 1245–1254 (2016).
pubmed: 26863403
doi: 10.1021/acschembio.5b01063
Dittus, L., Werner, T., Muelbaier, M. & Bantscheff, M. Differential kinobeads profiling for target identification of irreversible kinase inhibitors. ACS Chem. Biol. 12, 2515–2521 (2017).
pubmed: 28876896
doi: 10.1021/acschembio.7b00617
Bergamini, G. et al. A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation. Nat. Chem. Biol. 8, 576–582 (2012).
pubmed: 22544264
doi: 10.1038/nchembio.957
Liu, Y., Patricelli, M. P. & Cravatt, B. F. Activity-based protein profiling: the serine hydrolases. Proc. Natl Acad. Sci. USA 96, 14694–14699 (1999). This article is a landmark study that introduces activity-based protein profiling.
pubmed: 10611275
pmcid: 24710
doi: 10.1073/pnas.96.26.14694
Patricelli, M. P. et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350–358 (2007).
pubmed: 17209545
doi: 10.1021/bi062142x
Salisbury, C. M. & Cravatt, B. F. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J. Am. Chem. Soc. 130, 2184–2194 (2008).
pubmed: 18217751
doi: 10.1021/ja074138u
Joberty, G. et al. Interrogating the druggability of the 2-oxoglutarate-dependent dioxygenase target class by chemical proteomics. ACS Chem. Biol. 11, 2002–2010 (2016).
pubmed: 27197014
doi: 10.1021/acschembio.6b00080
Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255–265 (2011).
pubmed: 21258344
doi: 10.1038/nbt.1759
Altun, M. et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 18, 1401–1412 (2011).
pubmed: 22118674
doi: 10.1016/j.chembiol.2011.08.018
Fleischer, T. C. et al. Chemical proteomics identifies nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 17, 659–664 (2010).
pubmed: 20609415
doi: 10.1016/j.chembiol.2010.05.008
Eckert, M. A. et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature 569, 723–728 (2019).
pubmed: 31043742
pmcid: 6690743
doi: 10.1038/s41586-019-1173-8
Horning, B. D. et al. Chemical proteomic profiling of human methyltransferases. J. Am. Chem. Soc. 138, 13335–13343 (2016).
pubmed: 27689866
pmcid: 5072128
doi: 10.1021/jacs.6b07830
Li, X. et al. Chemical proteomic profiling of bromodomains enables the wide-spectrum evaluation of bromodomain inhibitors in living cells. J. Am. Chem. Soc. 141, 11497–11505 (2019).
pubmed: 31246451
doi: 10.1021/jacs.9b02738
Castello, A., Hentze, M. W. & Preiss, T. Metabolic enzymes enjoying new partnerships as RNA-binding proteins. Trends Endocrinol. Metab. 26, 746–757 (2015).
pubmed: 26520658
pmcid: 4671484
doi: 10.1016/j.tem.2015.09.012
Mittler, G., Butter, F. & Mann, M. A SILAC-based DNA protein interaction screen that identifies candidate binding proteins to functional DNA elements. Genome Res. 19, 284–293 (2009).
pubmed: 19015324
pmcid: 2652210
doi: 10.1101/gr.081711.108
Lomenick, B., Olsen, R. W. & Huang, J. Identification of direct protein targets of small molecules. ACS Chem. Biol. 6, 34–46 (2011).
pubmed: 21077692
doi: 10.1021/cb100294v
West, G. M., Tang, L. & Fitzgerald, M. C. Thermodynamic analysis of protein stability and ligand binding using a chemical modification- and mass spectrometry-based strategy. Anal. Chem. 80, 4175–4185 (2008).
pubmed: 18457414
doi: 10.1021/ac702610a
Huber, K. V. M. et al. Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. Nat. Methods 12, 1055–1057 (2015).
pubmed: 26389571
pmcid: 4629415
doi: 10.1038/nmeth.3590
Reinhard, F. B. M. et al. Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nat. Methods 12, 1129–1131 (2015).
pubmed: 26524241
doi: 10.1038/nmeth.3652
Leuenberger, P. et al. Cell-wide analysis of protein thermal unfolding reveals determinants of thermostability. Science 355, eaai7825 (2017).
pubmed: 28232526
doi: 10.1126/science.aai7825
Savitski, M. M. et al. Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis. Cell 173, 260–274.e225 (2018).
pubmed: 29551266
pmcid: 5871718
doi: 10.1016/j.cell.2018.02.030
Becher, I. et al. Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat. Nat. Chem. Biol. 12, 908–910 (2016).
pubmed: 27669419
doi: 10.1038/nchembio.2185
Kawatkar, A. et al. CETSA beyond soluble targets: a broad application to multipass transmembrane proteins. ACS Chem. Biol. 14, 1913–1920 (2019).
pubmed: 31329413
doi: 10.1021/acschembio.9b00399
Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100–2122 (2014).
pubmed: 25101824
doi: 10.1038/nprot.2014.138
Becher, I. et al. Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem. Biol. 9, 1736–1746 (2014).
pubmed: 24877719
doi: 10.1021/cb500235n
Perrin, J. et al. Identifying drug targets in tissues and whole blood with thermal-shift profiling. Nat. Biotechnol. 38, 303–308 (2020).
pubmed: 31959954
doi: 10.1038/s41587-019-0388-4
Li, J. et al. TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. Nat. Methods 17, 399–404 (2020).
pubmed: 32203386
pmcid: 7302421
doi: 10.1038/s41592-020-0781-4
Gaetani, M. et al. Proteome integral solubility alteration: a high-throughput proteomics assay for target deconvolution. J. Proteome Res. 18, 4027–4037 (2019).
pubmed: 31545609
doi: 10.1021/acs.jproteome.9b00500
Piazza, I. et al. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Nat. Commun. 11, 4200 (2020).
pubmed: 32826910
pmcid: 7442650
doi: 10.1038/s41467-020-18071-x
Ghaemmaghami, S., Fitzgerald, M. C. & Oas, T. G. A quantitative, high-throughput screen for protein stability. Proc. Natl Acad. Sci. USA 97, 8296–8301 (2000).
pubmed: 10890887
pmcid: 26941
doi: 10.1073/pnas.140111397
Masson, G. R., Maslen, S. L. & Williams, R. L. Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry. Biochem. J. 474, 1867–1877 (2017).
pubmed: 28381646
doi: 10.1042/BCJ20170127
Robinson, T. J. W. et al. High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors. Cell Cycle 12, 3013–3024 (2013).
pubmed: 23974104
pmcid: 3875676
doi: 10.4161/cc.26063
Henderson, M. J., Holbert, M. A., Simeonov, A. & Kallal, L. A. High-throughput cellular thermal shift assays in research and drug discovery. SLAS Discov. 25, 137–147 (2020).
pubmed: 31566060
doi: 10.1177/2472555219877183
Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014).
pubmed: 24203711
doi: 10.1093/nar/gkt1068
Lemmon, M. A., Schlessinger, J. & Ferguson, K. M. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol. 6, a020768 (2014).
pubmed: 24691965
pmcid: 3970421
doi: 10.1101/cshperspect.a020768
Lappano, R. & Maggiolini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47–60 (2011).
pubmed: 21193867
doi: 10.1038/nrd3320
Noberini, R., Sigismondo, G. & Bonaldi, T. The contribution of mass spectrometry-based proteomics to understanding epigenetics. Epigenomics 8, 429–445 (2016).
pubmed: 26606673
doi: 10.2217/epi.15.108
Kelly, T. K., De Carvalho, D. D. & Jones, P. A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28, 1069–1078 (2010).
pubmed: 20944599
pmcid: 3022972
doi: 10.1038/nbt.1678
Wilhelm, M. et al. Mass-spectrometry-based draft of the human proteome. Nature 509, 582–587 (2014). This article provides the first draft of the human proteome.
pubmed: 24870543
doi: 10.1038/nature13319
Liu, Y., Beyer, A. & Aebersold, R. On the dependency of cellular protein levels on mRNA Abundance. Cell 165, 535–550 (2016).
pubmed: 27104977
doi: 10.1016/j.cell.2016.03.014
Qin, P. et al. Activation of the amino acid response pathway blunts the effects of cardiac stress. J. Am. Heart Assoc. 6, e004453 (2017).
pubmed: 28487390
pmcid: 5524058
doi: 10.1161/JAHA.116.004453
Liu, W., Yuan, J., Liu, Z., Zhang, J. & Chang, J. Label-free quantitative proteomics combined with biological validation reveals activation of wnt/beta-catenin pathway contributing to trastuzumab resistance in gastric cancer. Int. J. Mol. Sci. 19, 1981 (2018).
pmcid: 6073113
doi: 10.3390/ijms19071981
Lamb, J. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 7, 54–60 (2007). This Review introduces CMAP, transcriptional expression data to probe relationships between cell physiology, diseases and drugs.
pubmed: 17186018
doi: 10.1038/nrc2044
Ruprecht, B. et al. A mass spectrometry-based proteome map of drug action in lung cancer cell lines. Nat. Chem. Biol. 16, 1111–1119 (2020).
pubmed: 32690943
doi: 10.1038/s41589-020-0572-3
Saei, A. A. et al. ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. Nat. Commun. 10, 5715 (2019).
pubmed: 31844049
pmcid: 6915695
doi: 10.1038/s41467-019-13582-8
Francavilla, C. et al. Multilayered proteomics reveals molecular switches dictating ligand-dependent EGFR trafficking. Nat. Struct. Mol. Biol. 23, 608–618 (2016).
pubmed: 27136326
doi: 10.1038/nsmb.3218
Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature 523, 183–188 (2015).
pubmed: 26131937
pmcid: 4853910
doi: 10.1038/nature14610
Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019).
pubmed: 31666732
doi: 10.1038/s41573-019-0047-y
Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101–114 (2017).
pubmed: 27885283
doi: 10.1038/nrd.2016.211
Ong, S.-E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteom. 1, 376–386 (2002). This article is a foundational study for quantitative proteomics.
doi: 10.1074/mcp.M200025-MCP200
Larance, M., Ahmad, Y., Kirkwood, K. J., Ly, T. & Lamond, A. I. Global subcellular characterization of protein degradation using quantitative proteomics. Mol. Cell Proteom. 12, 638–650 (2013).
doi: 10.1074/mcp.M112.024547
Schwanhäusser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342 (2011).
pubmed: 21593866
doi: 10.1038/nature10098
Mathieson, T. et al. Systematic analysis of protein turnover in primary cells. Nat. Commun. 9, 689 (2018).
pubmed: 29449567
pmcid: 5814408
doi: 10.1038/s41467-018-03106-1
Tharkeshwar, A. K., Gevaert, K. & Annaert, W. Organellar omics — a reviving strategy to untangle the biomolecular complexity of the cell. Proteomics 18, e1700113 (2018).
pubmed: 29125683
doi: 10.1002/pmic.201700113
Swietlik, J. J., Sinha, A. & Meissner, F. Dissecting intercellular signaling with mass spectrometry-based proteomics. Curr. Opin. Cell Biol. 63, 20–30 (2020).
pubmed: 31927463
doi: 10.1016/j.ceb.2019.12.002
Kalxdorf, M. et al. Cell surface thermal proteome profiling tracks perturbations and drug targets on the plasma membrane. Nat. Methods 18, 84–91 (2021).
pubmed: 33398190
doi: 10.1038/s41592-020-01022-1
Lundberg, E. & Borner, G. H. H. Spatial proteomics: a powerful discovery tool for cell biology. Nat. Rev. Mol. Cell Biol. 20, 285–302 (2019).
pubmed: 30659282
doi: 10.1038/s41580-018-0094-y
Andersen, J. S. et al. Proteomic characterization of the human centrosome by protein correlation profiling. Nature 426, 570–574 (2003).
pubmed: 14654843
doi: 10.1038/nature02166
Itzhak, D. N., Tyanova, S., Cox, J. & Borner, G. H. Global, quantitative and dynamic mapping of protein subcellular localization. eLife 5, e16950 (2016).
pubmed: 27278775
pmcid: 4959882
doi: 10.7554/eLife.16950
Geladaki, A. et al. Combining LOPIT with differential ultracentrifugation for high-resolution spatial proteomics. Nat. Commun. 10, 331 (2019).
pubmed: 30659192
pmcid: 6338729
doi: 10.1038/s41467-018-08191-w
Orre, L. M. et al. SubCellBarCode: proteome-wide mapping of protein localization and relocalization. Mol. Cell 73, 166–182 e167 (2019).
pubmed: 30609389
doi: 10.1016/j.molcel.2018.11.035
Kristensen, A. R., Gsponer, J. & Foster, L. J. A high-throughput approach for measuring temporal changes in the interactome. Nat. Methods 9, 907–909 (2012).
pubmed: 22863883
pmcid: 3954081
doi: 10.1038/nmeth.2131
Heusel, M. et al. Complex-centric proteome profiling by SEC-SWATH-MS. Mol. Syst. Biol. 15, e8438 (2019).
pubmed: 30642884
pmcid: 6346213
doi: 10.15252/msb.20188438
Rhee, H. W. et al. Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. Science 339, 1328–1331 (2013).
pubmed: 23371551
pmcid: 3916822
doi: 10.1126/science.1230593
Roux, K. J., Kim, D. I., Raida, M. & Burke, B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J. Cell Biol. 196, 801–810 (2012).
pubmed: 22412018
pmcid: 3308701
doi: 10.1083/jcb.201112098
Youn, J. Y. et al. High-density proximity mapping reveals the subcellular organization of mrna-associated granules and bodies. Mol. Cell 69, 517–532 e511 (2018).
pubmed: 29395067
doi: 10.1016/j.molcel.2017.12.020
Loh, K. H. et al. Proteomic analysis of unbounded cellular compartments: synaptic clefts. Cell 166, 1295–1307.e1221 (2016).
pubmed: 27565350
pmcid: 5167540
doi: 10.1016/j.cell.2016.07.041
Gupta, G. D. et al. A dynamic protein interaction landscape of the human centrosome-cilium interface. Cell 163, 1484–1499 (2015).
pubmed: 26638075
pmcid: 5089374
doi: 10.1016/j.cell.2015.10.065
Li, J. et al. Cell-surface proteomic profiling in the fly brain uncovers wiring regulators. Cell 180, 373–386.e315 (2020).
pubmed: 31955847
pmcid: 7072036
doi: 10.1016/j.cell.2019.12.029
Branon, T. C. et al. Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 36, 880–887 (2018).
pubmed: 30125270
pmcid: 6126969
doi: 10.1038/nbt.4201
Paek, J. et al. Multidimensional tracking of GPCR signaling via peroxidase-catalyzed proximity labeling. Cell 169, 338–349.e311 (2017).
pubmed: 28388415
pmcid: 5514552
doi: 10.1016/j.cell.2017.03.028
Lobingier, B. T. et al. An approach to spatiotemporally resolve protein interaction networks in living cells. Cell 169, 350–360.e312 (2017).
pubmed: 28388416
pmcid: 5616215
doi: 10.1016/j.cell.2017.03.022
Geri, J. B. et al. Microenvironment mapping via Dexter energy transfer on immune cells. Science 367, 1091–1097 (2020).
pubmed: 32139536
pmcid: 7336666
doi: 10.1126/science.aay4106
Gingras, A. C., Abe, K. T. & Raught, B. Getting to know the neighborhood: using proximity-dependent biotinylation to characterize protein complexes and map organelles. Curr. Opin. Chem. Biol. 48, 44–54 (2019).
pubmed: 30458335
doi: 10.1016/j.cbpa.2018.10.017
Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug Discov. 15, 533–550 (2016).
pubmed: 27050677
doi: 10.1038/nrd.2016.29
Zeng, L. et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 127, 2376–2377 (2005).
pubmed: 15724976
doi: 10.1021/ja044885g
Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010). This article reports the discovery of JQ1 as a selective inhibitor of BET proteins.
pubmed: 20871596
pmcid: 3010259
doi: 10.1038/nature09504
Smith, K. T., Martin-Brown, S. A., Florens, L., Washburn, M. P. & Workman, J. L. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chem. Biol. 17, 65–74 (2010).
pubmed: 20142042
pmcid: 2819981
doi: 10.1016/j.chembiol.2009.12.010
Ser, Z., Cifani, P. & Kentsis, A. Optimized cross-linking mass spectrometry for in situ interaction proteomics. J. Proteome Res. 18, 2545–2558 (2019).
pubmed: 31083951
pmcid: 7473601
doi: 10.1021/acs.jproteome.9b00085
Sinz, A. Cross-linking/mass spectrometry for studying protein structures and protein-protein interactions: where are we now and where should we go from here? Angew. Chem. Int. Ed. Engl. 57, 6390–6396 (2018).
pubmed: 29334167
doi: 10.1002/anie.201709559
Choudhary, C. et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell 36, 326–339 (2009).
pubmed: 19854140
doi: 10.1016/j.molcel.2009.09.019
Christensen, G. L. et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol. Cell Proteom. 9, 1540–1553 (2010).
doi: 10.1074/mcp.M900550-MCP200
Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).
pubmed: 29191878
pmcid: 6542668
doi: 10.1126/science.aan4368
Zhuang, G. et al. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci. Signal. 6, ra25 (2013).
pubmed: 23592840
Li, J. et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 6, 291–299 (2010).
pubmed: 20190765
pmcid: 2842457
doi: 10.1038/nchembio.332
Rexer, B. N. et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 30, 4163–4174 (2011).
pubmed: 21499296
pmcid: 3204390
doi: 10.1038/onc.2011.130
Boyer, A. P., Collier, T. S., Vidavsky, I. & Bose, R. Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol. Cell Proteom. 12, 180–193 (2013).
doi: 10.1074/mcp.M112.020115
Gundry, J., Glenn, R., Alagesan, P. & Rajagopal, S. A practical guide to approaching biased agonism at G protein coupled receptors. Front. Neurosci. 11, 17 (2017).
pubmed: 28174517
pmcid: 5258729
doi: 10.3389/fnins.2017.00017
Tsvetanova, N. G. et al. G protein-coupled receptor endocytosis confers uniformity in responses to chemically distinct ligands. Mol. Pharmacol. 91, 145–156 (2017).
pubmed: 27879340
pmcid: 5267521
doi: 10.1124/mol.116.106369
Stebbing, J. et al. The regulatory roles of phosphatases in cancer. Oncogene 33, 939–953 (2014).
pubmed: 23503460
doi: 10.1038/onc.2013.80
Lyons, S. P. et al. A quantitative chemical proteomic strategy for profiling phosphoprotein phosphatases from yeast to humans. Mol. Cell Proteom. 17, 2448–2461 (2018).
doi: 10.1074/mcp.RA118.000822
Humphrey, S. J., Azimifar, S. B. & Mann, M. High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics. Nat. Biotechnol. 33, 990–995 (2015).
pubmed: 26280412
doi: 10.1038/nbt.3327
Liu, J. J. et al. In vivo brain GPCR signaling elucidated by phosphoproteomics. Science 360, eaao4927 (2018).
pubmed: 29930108
pmcid: 6527112
doi: 10.1126/science.aao4927
Lundby, A. et al. Oncogenic mutations rewire signaling pathways by switching protein recruitment to phosphotyrosine sites. Cell 179, 543–560.e526 (2019).
pubmed: 31585087
doi: 10.1016/j.cell.2019.09.008
Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009). This article provides a global analysis of lysine acetylation.
pubmed: 19608861
doi: 10.1126/science.1175371
Schölz, C. et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat. Biotechnol. 33, 415–423 (2015).
pubmed: 25751058
doi: 10.1038/nbt.3130
Kranke, B., Szolar-Platzer, C., Komericki, P., Derhaschnig, J. & Aberer, W. Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer. Contact Dermat. 36, 212–215 (1997).
doi: 10.1111/j.1600-0536.1997.tb00272.x
Kim, W. et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44, 325–340 (2011).
pubmed: 21906983
pmcid: 3200427
doi: 10.1016/j.molcel.2011.08.025
Wagner, S. A. et al. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol. Cell Proteom. 10, M111 013284 (2011).
doi: 10.1074/mcp.M111.013284
Thompson, J. W. et al. Quantitative Lys — Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1. J. Biol. Chem. 289, 28942–28955 (2014).
pubmed: 25147182
pmcid: 4200252
doi: 10.1074/jbc.M114.573352
Reverdy, C. et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem. Biol. 19, 467–477 (2012).
pubmed: 22520753
doi: 10.1016/j.chembiol.2012.02.007
Schauer, N. J. et al. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci. Rep. 10, 5324 (2020).
pubmed: 32210275
pmcid: 7093416
doi: 10.1038/s41598-020-62076-x
Adam, K. & Hunter, T. Histidine kinases and the missing phosphoproteome from prokaryotes to eukaryotes. Lab. Invest. 98, 233–247 (2018).
pubmed: 29058706
doi: 10.1038/labinvest.2017.118
Tsiatsiani, L. & Heck, A. J. Proteomics beyond trypsin. FEBS J. 282, 2612–2626 (2015).
pubmed: 25823410
doi: 10.1111/febs.13287
Frauenstein, A. et al. Identification of covalent modifications regulating immune signaling complex composition and phenotype. Mol. Syst. Biol. 17, e10125 (2021).
pubmed: 34318608
pmcid: 8447602
doi: 10.15252/msb.202010125
Huang, J. X. et al. High throughput discovery of functional protein modifications by Hotspot Thermal Profiling. Nat. Methods 16, 894–901 (2019).
pubmed: 31384043
pmcid: 7238970
doi: 10.1038/s41592-019-0499-3
Potel, C. M. et al. Impact of phosphorylation on thermal stability of proteins. Nat. Methods 18, 757–759 (2021).
pubmed: 34140700
doi: 10.1038/s41592-021-01177-5
Chuh, K. N. & Pratt, M. R. Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr. Opin. Chem. Biol. 24, 27–37 (2015).
pubmed: 25461721
doi: 10.1016/j.cbpa.2014.10.020
Parker, C. G. & Pratt, M. R. Click chemistry in proteomic investigations. Cell 180, 605–632 (2020).
pubmed: 32059777
pmcid: 7087397
doi: 10.1016/j.cell.2020.01.025
Saxon, E. & Bertozzi, C. R. Cell surface engineering by a modified Staudinger reaction. Science 287, 2007–2010 (2000).
pubmed: 10720325
doi: 10.1126/science.287.5460.2007
Bos, J. & Muir, T. W. A chemical probe for protein crotonylation. J. Am. Chem. Soc. 140, 4757–4760 (2018).
pubmed: 29584949
pmcid: 6505473
doi: 10.1021/jacs.7b13141
Rowland, M. M. et al. Phosphatidylinositol 3,4,5-trisphosphate activity probes for the labeling and proteomic characterization of protein binding partners. Biochemistry 50, 11143–11161 (2011).
pubmed: 22074223
doi: 10.1021/bi201636s
Hang, H. C. et al. Chemical probes for the rapid detection of Fatty-acylated proteins in Mammalian cells. J. Am. Chem. Soc. 129, 2744–2745 (2007).
pubmed: 17305342
doi: 10.1021/ja0685001
Storck, E. M. et al. Dual chemical probes enable quantitative system-wide analysis of protein prenylation and prenylation dynamics. Nat. Chem. 11, 552–561 (2019).
pubmed: 30936521
pmcid: 6544531
doi: 10.1038/s41557-019-0237-6
Ostasiewicz, P., Zielinska, D. F., Mann, M. & Wisniewski, J. R. Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. J. Proteome Res. 9, 3688–3700 (2010).
pubmed: 20469934
doi: 10.1021/pr100234w
Borrebaeck, C. A. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat. Rev. Cancer 17, 199–204 (2017).
pubmed: 28154374
doi: 10.1038/nrc.2016.153
Mann, M., Kumar, C., Zeng, W. F. & Strauss, M. T. Artificial intelligence for proteomics and biomarker discovery. Cell Syst. 12, 759–770 (2021).
pubmed: 34411543
doi: 10.1016/j.cels.2021.06.006
Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007).
pubmed: 18083107
doi: 10.1016/j.cell.2007.11.025
Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342–6363 (2011).
pubmed: 21812414
doi: 10.1021/jm2007613
Dazert, E. et al. Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proc. Natl Acad. Sci. USA 113, 1381–1386 (2016).
pubmed: 26787912
pmcid: 4747770
doi: 10.1073/pnas.1523434113
Coscia, F. et al. A streamlined mass spectrometry-based proteomics workflow for large scale FFPE tissue analysis. J. Pathol. 251, 100–112 (2020).
pubmed: 32154592
doi: 10.1002/path.5420
Jiang, Y. et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 567, 257–261 (2019).
pubmed: 30814741
doi: 10.1038/s41586-019-0987-8
Vasaikar, S. et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell 177, 1035–1049.e1019 (2019).
pubmed: 31031003
pmcid: 6768830
doi: 10.1016/j.cell.2019.03.030
Francavilla, C. et al. Phosphoproteomics of primary cells reveals druggable kinase signatures in ovarian cancer. Cell Rep. 18, 3242–3256 (2017).
pubmed: 28355574
pmcid: 5382236
doi: 10.1016/j.celrep.2017.03.015
Sinha, A. et al. The proteogenomic landscape of curable prostate cancer. Cancer Cell 35, 414–427.e416 (2019).
pubmed: 30889379
pmcid: 6511374
doi: 10.1016/j.ccell.2019.02.005
Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55–62 (2016).
pubmed: 27251275
pmcid: 5102256
doi: 10.1038/nature18003
Archer, T. C. et al. Proteomics, post-translational modifications, and integrative analyses reveal molecular heterogeneity within medulloblastoma subgroups. Cancer Cell 34, 396–410.e398 (2018).
pubmed: 30205044
pmcid: 6372116
doi: 10.1016/j.ccell.2018.08.004
Steger, M. et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. eLife 5, e12813 (2016). This paper reveals Rab proteins as the long-sought substrate of LRRK2.
pubmed: 26824392
pmcid: 4769169
doi: 10.7554/eLife.12813
Karayel, O. et al. Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 activity in Parkinson’s disease. Mol. Cell Proteom. 19, 1546–1560 (2020).
doi: 10.1074/mcp.RA120.002055
Pankow, S. et al. ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature 528, 510–516 (2015).
pubmed: 26618866
pmcid: 4826614
doi: 10.1038/nature15729
Caron, E. et al. Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry. Mol. Cell. Proteom. 14, 3105–3117 (2015).
doi: 10.1074/mcp.O115.052431
Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 10, eaau5516 (2018).
pubmed: 30518613
doi: 10.1126/scitranslmed.aau5516
Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803–808 (2015).
pubmed: 25837513
pmcid: 4549796
doi: 10.1126/science.aaa3828
Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).
pubmed: 27869121
pmcid: 5121339
doi: 10.1038/ncomms13404
Coscia, F. et al. Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer. Cell 175, 159–170.e116 (2018).
pubmed: 30241606
pmcid: 6827878
doi: 10.1016/j.cell.2018.08.065
Papoian, T. et al. Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective. Nat. Rev. Drug Discov. 14, 294 (2015).
pubmed: 25792260
doi: 10.1038/nrd3845-c1
Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909–922 (2012).
pubmed: 23197038
doi: 10.1038/nrd3845
Mellor, H. R., Bell, A. R., Valentin, J. P. & Roberts, R. R. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120, 14–32 (2011).
pubmed: 21177772
doi: 10.1093/toxsci/kfq378
Force, T. & Kolaja, K. L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111–126 (2011).
pubmed: 21283106
doi: 10.1038/nrd3252
Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769–784 (2006).
pubmed: 16955068
doi: 10.1038/nrd2133
Reddy, A. S. & Zhang, S. Polypharmacology: drug discovery for the future. Expert Rev. Clin. Pharmacol. 6, 41–47 (2013).
pubmed: 23272792
doi: 10.1586/ecp.12.74
Siehl, J. & Thiel, E. C-kit, GIST, and imatinib. Recent. Results Cancer Res. 176, 145–151 (2007).
pubmed: 17607922
doi: 10.1007/978-3-540-46091-6_12
Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561–566 (1996). This article contains the first description of the efficacy of glivec/imatinib in chronic myeloid leukaemia.
pubmed: 8616716
doi: 10.1038/nm0596-561
Vinken, M. The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312, 158–165 (2013).
pubmed: 23978457
doi: 10.1016/j.tox.2013.08.011
Huang, L. H. et al. ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 46, D911–D917 (2018).
pubmed: 30053268
doi: 10.1093/nar/gkx899
Medard, G. et al. Optimized chemical proteomics assay for kinase inhibitor profiling. J. Proteome Res. 14, 1574–1586 (2015).
pubmed: 25660469
doi: 10.1021/pr5012608
Golkowski, M. et al. Kinobead and single-shot LC-MS profiling identifies selective PKD inhibitors. J. Proteome Res. 16, 1216–1227 (2017).
pubmed: 28102076
pmcid: 5663466
doi: 10.1021/acs.jproteome.6b00817
Zuhl, A. M. et al. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of beta-secretase inhibitors. Nat. Commun. 7, 13042 (2016).
pubmed: 27727204
pmcid: 5062570
doi: 10.1038/ncomms13042
Butler, D. & Callaway, E. Scientists in the dark after French clinical trial proves fatal. Nature 529, 263–264 (2016).
pubmed: 26791697
doi: 10.1038/nature.2016.19189
van Esbroeck, A. C. M. et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science 356, 1084–1087 (2017).
pubmed: 28596366
pmcid: 5641481
doi: 10.1126/science.aaf7497
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S. & Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805–815 (2006).
pubmed: 16841068
doi: 10.1038/nbt1228
Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536–541 (2015).
pubmed: 26196764
pmcid: 4706458
doi: 10.1038/nchembio.1867
Dittmann, A. et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 9, 495–502 (2013).
pubmed: 24533473
doi: 10.1021/cb400789e
Gharbi, S. I. et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404, 15–21 (2007).
pubmed: 17302559
pmcid: 1868829
doi: 10.1042/BJ20061489
Ciceri, P. et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 10, 305–312 (2014).
pubmed: 24584101
pmcid: 3998711
doi: 10.1038/nchembio.1471
Munoz, L. Non-kinase targets of protein kinase inhibitors. Nat. Rev. Drug Discov. 16, 424–440 (2017).
pubmed: 28280261
doi: 10.1038/nrd.2016.266
Kwiatkowski, N. et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616–620 (2014).
pubmed: 25043025
pmcid: 4244910
doi: 10.1038/nature13393
Lacouture, M. E. et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18, 314–322 (2013).
pubmed: 23457002
pmcid: 3607529
doi: 10.1634/theoncologist.2012-0333
Elkins, J. M. et al. Comprehensive characterization of the published kinase inhibitor set. Nat. Biotechnol. 34, 95–103 (2015).
pubmed: 26501955
doi: 10.1038/nbt.3374
van Vliet, D. et al. Infants with tyrosinemia type 1: should phenylalanine be supplemented? JIMD Rep. 18, 117–124 (2015).
pubmed: 25256450
doi: 10.1007/8904_2014_358
Yang, X. & Bartlett, M. G. Identification of protein adduction using mass spectrometry: protein adducts as biomarkers and predictors of toxicity mechanisms. Rapid Commun. Mass. Spectrom. 30, 652–664 (2016).
pubmed: 26842586
doi: 10.1002/rcm.7462
Uetrecht, J. Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol. 47, 513–539 (2007).
pubmed: 16879083
doi: 10.1146/annurev.pharmtox.47.120505.105150
Lanning, B. R. et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10, 760–767 (2014).
pubmed: 25038787
pmcid: 4138289
doi: 10.1038/nchembio.1582
Johnson, D. S., Weerapana, E. & Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2, 949–964 (2010).
pubmed: 20640225
doi: 10.4155/fmc.10.21
Liu, N. et al. Direct and two-step bioorthogonal probes for Bruton’s tyrosine kinase based on ibrutinib: a comparative study. Org. Biomol. Chem. 13, 5147–5157 (2015).
pubmed: 25849561
doi: 10.1039/C5OB00474H
Federspiel, J. D. et al. Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells. Mol. Cell. Proteom. 15, 3233–3242 (2016).
doi: 10.1074/mcp.M116.059709
Whitby, L. R., Obach, R. S., Simon, G. M., Hayward, M. M. & Cravatt, B. F. Quantitative chemical proteomic profiling of the in vivo targets of reactive drug metabolites. ACS Chem. Biol. 12, 2040–2050 (2017).
pubmed: 28636309
pmcid: 5626524
doi: 10.1021/acschembio.7b00346
Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790–795 (2010). This study provides an analytical framework to assess selectivity when targeting functional cysteine residues in proteins with covalent strategies.
pubmed: 21085121
pmcid: 3058684
doi: 10.1038/nature09472
Sun, R. et al. A chemoproteomic platform to assess bioactivation potential of drugs. Chem. Res. Toxicol. 30, 1797–1803 (2017).
pubmed: 28960974
doi: 10.1021/acs.chemrestox.7b00183
Hodgman, M. J. & Garrard, A. R. A review of acetaminophen poisoning. Crit. Care Clin. 28, 499–516 (2012).
pubmed: 22998987
doi: 10.1016/j.ccc.2012.07.006
Bruderer, R. et al. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. Mol. Cell. Proteom. 14, 1400–1410 (2015).
doi: 10.1074/mcp.M114.044305
Tailor, A., Waddington, J. C., Meng, X. & Park, B. K. Mass spectrometric and functional aspects of drug-protein conjugation. Chem. Res. Toxicol. 29, 1912–1935 (2016).
pubmed: 27689879
doi: 10.1021/acs.chemrestox.6b00147
Illing, P. T. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486, 554–558 (2012).
pubmed: 22722860
doi: 10.1038/nature11147
Long, M. J. C. & Aye, Y. Privileged electrophile sensors: a resource for covalent drug development. Cell Chem. Biol. 24, 787–800 (2017).
pubmed: 28648380
pmcid: 5528179
doi: 10.1016/j.chembiol.2017.05.023
Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307–317 (2011).
pubmed: 21455239
doi: 10.1038/nrd3410
Garber, K. Kinase inhibitors overachieve in CLL. Nat. Rev. Drug Discov. 13, 162–164 (2014).
pubmed: 24549135
doi: 10.1038/nrd4259
Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578–589.e517 (2018). This paper reports the discovery of ARS-1620, which laid the foundation for present clinical G12C-specific KRAS inhibitors.
pubmed: 29373830
doi: 10.1016/j.cell.2018.01.006
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).
pubmed: 31666701
doi: 10.1038/s41586-019-1694-1
Flanagan, M. E. et al. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J. Med. Chem. 57, 10072–10079 (2014).
pubmed: 25375838
doi: 10.1021/jm501412a
Powers, J. C., Asgian, J. L., Ekici, O. D. & James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639–4750 (2002).
pubmed: 12475205
doi: 10.1021/cr010182v
Niphakis, M. J. et al. A global map of lipid-binding proteins and their ligandability in cells. Cell 161, 1668–1680 (2015).
pubmed: 26091042
pmcid: 4615699
doi: 10.1016/j.cell.2015.05.045
Kambe, T., Correia, B. E., Niphakis, M. J. & Cravatt, B. F. Mapping the protein interaction landscape for fully functionalized small-molecule probes in human cells. J. Am. Chem. Soc. 136, 10777–10782 (2014).
pubmed: 25045785
pmcid: 4120992
doi: 10.1021/ja505517t
Backus, K. M. et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534, 570–574 (2016). This article redefines the chemogenomics target space by covalent ligands.
pubmed: 27309814
pmcid: 4919207
doi: 10.1038/nature18002
Johansson, H. et al. Fragment-based covalent ligand screening enables rapid discovery of inhibitors for the RBR E3 ubiquitin ligase HOIP. J. Am. Chem. Soc. 141, 2703–2712 (2019).
pubmed: 30657686
pmcid: 6383986
doi: 10.1021/jacs.8b13193
Kuljanin, M. et al. Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries. Nat. Biotechnol. 39, 630–641 (2021).
pubmed: 33398154
pmcid: 8316984
doi: 10.1038/s41587-020-00778-3
Boike, L. et al. Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. Cell Chem. Biol. 28, 4–13.e17 (2021).
pubmed: 32966806
doi: 10.1016/j.chembiol.2020.09.001
Hacker, S. M. et al. Global profiling of lysine reactivity and ligandability in the human proteome. Nat. Chem. 9, 1181–1190 (2017).
pubmed: 29168484
pmcid: 5726523
doi: 10.1038/nchem.2826
Lin, S. et al. Redox-based reagents for chemoselective methionine bioconjugation. Science 355, 597–602 (2017).
pubmed: 28183972
pmcid: 5827972
doi: 10.1126/science.aal3316
Hahm, H. S. et al. Global targeting of functional tyrosines using sulfur-triazole exchange chemistry. Nat. Chem. Biol. 16, 150–159 (2020).
pubmed: 31768034
doi: 10.1038/s41589-019-0404-5
Gehringer, M. & Laufer, S. A. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J. Med. Chem. 62, 5673–5724 (2019).
pubmed: 30565923
doi: 10.1021/acs.jmedchem.8b01153
Evans, M. J., Saghatelian, A., Sorensen, E. J. & Cravatt, B. F. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 23, 1303–1307 (2005).
pubmed: 16200062
doi: 10.1038/nbt1149
Evans, M. J. et al. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol. Biosyst. 3, 495 (2007).
pubmed: 17579775
doi: 10.1039/b705113a
Parker, C. G. et al. Ligand and target discovery by fragment-based screening in human cells. Cell 168, 527–541.e529 (2017).
pubmed: 28111073
pmcid: 5632530
doi: 10.1016/j.cell.2016.12.029
Wang, Y. et al. Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs. Nat. Chem. 11, 1113–1123 (2019).
pubmed: 31659311
pmcid: 6874898
doi: 10.1038/s41557-019-0351-5
Jones, L. H. Expanding chemogenomic space using chemoproteomics. Bioorg. Med. Chem. 27, 3451–3453 (2019).
pubmed: 31221609
doi: 10.1016/j.bmc.2019.06.022
Conway, L. P., Li, W. & Parker, C. G. Chemoproteomic-enabled phenotypic screening. Cell Chem. Biol. 28, 371–393 (2021).
pubmed: 33577749
doi: 10.1016/j.chembiol.2021.01.012
Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638–654 (2021).
pubmed: 34131295
pmcid: 8463487
doi: 10.1038/s41568-021-00365-x
Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. eLife 7, e38430 (2018).
pubmed: 30067223
pmcid: 6156078
doi: 10.7554/eLife.38430
Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).
pubmed: 26075522
pmcid: 4629852
doi: 10.1038/nchembio.1858
Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015). The above two articles relate to breakthrough studies that sparked renewed interest in targeted degradation as therapeutic strategy.
pubmed: 25999370
pmcid: 4937790
doi: 10.1126/science.aab1433
Marx, V. A dream of single-cell proteomics. Nat. Methods 16, 809–812 (2019).
pubmed: 31406385
doi: 10.1038/s41592-019-0540-6
Specht, H. & Slavov, N. Transformative opportunities for single-cell proteomics. J. Proteome Res. 17, 2565–2571 (2018).
pubmed: 29945450
pmcid: 6089608
doi: 10.1021/acs.jproteome.8b00257
Mund, A. et al. AI-driven Deep Visual Proteomics defines cell identity and heterogeneity. Preprint at bioRxiv https://doi.org/10.1101/2021.01.25.427969 (2021).
doi: 10.1101/2021.01.25.427969
Fu, Q. et al. Highly reproducible automated proteomics sample preparation workflow for quantitative mass spectrometry. J. Proteome Res. 17, 420–428 (2018).
pubmed: 29083196
doi: 10.1021/acs.jproteome.7b00623
Muller, T. et al. Automated sample preparation with SP3 for low-input clinical proteomics. Mol. Syst. Biol. 16, e9111 (2020).
pubmed: 32129943
pmcid: 6966100
doi: 10.15252/msb.20199111
Messner, C. B. et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 11, 11–24.e4 (2020).
pubmed: 32619549
pmcid: 7264033
doi: 10.1016/j.cels.2020.05.012
Geyer, P. E. et al. Plasma proteome profiling to assess human health and disease. Cell Syst. 2, 185–195 (2016).
pubmed: 27135364
doi: 10.1016/j.cels.2016.02.015
Riley, N. M., Hebert, A. S. & Coon, J. J. Proteomics moves into the fast lane. Cell Syst. 2, 142–143 (2016).
pubmed: 27135360
doi: 10.1016/j.cels.2016.03.002
Nahnsen, S., Bielow, C., Reinert, K. & Kohlbacher, O. Tools for label-free peptide quantification. Mol. Cell. Proteom. 12, 549–556 (2013).
doi: 10.1074/mcp.R112.025163
Gillet, L. C. et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell Proteom. 11, O111 016717 (2012).
doi: 10.1074/mcp.O111.016717
Thompson, A. et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895–1904 (2003). This paper introduces a new concept for chemical labels to enable relative and absolute protein quantification.
pubmed: 12713048
doi: 10.1021/ac0262560
Virreira Winter, S. et al. EASI-tag enables accurate multiplexed and interference-free MS2-based proteome quantification. Nat. Methods 15, 527–530 (2018).
pubmed: 29915187
doi: 10.1038/s41592-018-0037-8
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008). This paper introduces the most frequently used and free software suite in proteomics.
pubmed: 19029910
doi: 10.1038/nbt.1511
Zhang, J. et al. PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. Mol. Cell Proteom. 11, M111 010587 (2012).
doi: 10.1074/mcp.M111.010587
Sinitcyn, P., Rudolph, J. D. & Cox, J. Computational methods for understanding mass spectrometry–based shotgun proteomics data. Annu. Rev. Biomed. Data Sci. 1, 207–234 (2018).
doi: 10.1146/annurev-biodatasci-080917-013516
Tsiamis, V. et al. One thousand and one software for proteomics: tales of the toolmakers of science. J. Proteome Res. 18, 3580–3585 (2019).
pubmed: 31429284
doi: 10.1021/acs.jproteome.9b00219
Martens, L. & Vizcaino, J. A. A golden age for working with public proteomics data. Trends Biochem. Sci. 42, 333–341 (2017).
pubmed: 28118949
pmcid: 5414595
doi: 10.1016/j.tibs.2017.01.001
Kim, M. S. et al. A draft map of the human proteome. Nature 509, 575–581 (2014). This article reports the first draft of the human proteome.
pubmed: 24870542
pmcid: 4403737
doi: 10.1038/nature13302
Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
pubmed: 25613900
doi: 10.1126/science.1260419
Thul, P. J. et al. A subcellular map of the human proteome. Science 356, eaal3321 (2017).
pubmed: 28495876
doi: 10.1126/science.aal3321
Go, C. D. et al. A proximity biotinylation map of a human cell. Preprint at bioRxiv https://doi.org/10.1101/796391 (2019).
doi: 10.1101/796391
Huttlin, E. L. et al. Architecture of the human interactome defines protein communities and disease networks. Nature 545, 505–509 (2017).
pubmed: 28514442
pmcid: 5531611
doi: 10.1038/nature22366
Hein, M. Y. et al. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 163, 712–723 (2015). The above two references describe some of the deepest and information-rich high-quality interactome studies to date.
pubmed: 26496610
doi: 10.1016/j.cell.2015.09.053
Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015).
pubmed: 25514926
doi: 10.1093/nar/gku1267
Ochoa, D. et al. The functional landscape of the human phosphoproteome. Nat. Biotechnol. 38, 365–373 (2020).
pubmed: 31819260
doi: 10.1038/s41587-019-0344-3
Jarzab, A. et al. Meltome atlas-thermal proteome stability across the tree of life. Nat. Methods 17, 495–503 (2020).
pubmed: 32284610
doi: 10.1038/s41592-020-0801-4
Shao, W. et al. The SysteMHC Atlas project. Nucleic Acids Res. 46, D1237–D1247 (2018).
pubmed: 28985418
doi: 10.1093/nar/gkx664
UniProt, C. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506–D515 (2019).
doi: 10.1093/nar/gky1049
Choobdar, S. et al. Assessment of network module identification across complex diseases. Nat. Methods 16, 843–852 (2019).
pubmed: 31471613
pmcid: 6719725
doi: 10.1038/s41592-019-0509-5
Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. Genome Biol. 18, 83 (2017).
pubmed: 28476144
pmcid: 5418815
doi: 10.1186/s13059-017-1215-1